Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Quimioterapia más rituximab versus quimioterapia sola para el linfoma no Hodgkin de células B

Información

DOI:
https://doi.org/10.1002/14651858.CD003805.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 17 octubre 2007see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Hematología

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Holger Schulz

    Correspondencia a: Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

    [email protected]

  • Julia Bohlius

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Nicole Skoetz

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

  • Sven Trelle

    Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

  • Thilo Kober

    Smiling Press Productions, Scullin, Australia

  • Marcel Reiser

    Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany

  • Martin Dreyling

    Medizinische Klinik III, Klinikum der Universität München‐Großhadern, München, Germany

  • Michael Herold

    Medical Clinic Hematology/Oncology, 2. Medizinische Klinik, Helios Klinikum Erfurt, Erfurt, Germany

  • Guido Schwarzer

    Department of Medical Biometry and Statistics, German Cochrane Center, Freiburg, Germany

  • Michael Hallek

    Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany

  • Andreas Engert

    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

Contributions of authors

  • Holger Schulz: Conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.

  • Thilo Kober: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting and writing of final review

  • Julia Bohlius: Methodological advice, conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.

  • Andreas Engert: Clinical and scientific advice, conception and design, analysis and interpretation of data, writing of review and final approval.

  • Marcel Reiser: Conception and design, analysis and interpretation, writing of review and final approval.

  • Nicole Skoetz: Conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.

  • Martin Dreyling: provision of study material, data extraction, writing of review and final approval.

  • Michael Herold: provision of study material, writing of review and final approval.

  • Sven Trelle: Conception and design, methodological advice, data extraction, analysis and interpretation, writing of review and final approval.

  • Guido Schwarzer: Methodological advice, data analysis and interpretation, writing of review and final approval.

  • Michael Hallek: Clinical and scientific advice, writing of review and final approval.

Sources of support

Internal sources

  • Kompetence Network Malignant Lymphoma paid the salary for TK (1999‐2001), Germany.

External sources

  • The Editorial Base of CHMG is funded by the German Ministry of Education and Research (BMBF) FKZ : 01GH0501, Germany.

  • The Editorial Base gets additional funding by “Köln Fortune” the funding programme from the medical faculty University of Cologne, Germany.

Declarations of interest

Thilo Kober was up to March 2006 the co‐ordinator of the Cochrane Haematological Malignancies Group (CHMG) and was involved in the preparation of systematic reviews and other material for the Cochrane Library. Julia Bohlius is a medical officer and reviewer, Andreas Engert is the CHMG co‐ordinating editor and Holger Schulz is a medical officer and reviewer in the CHMG editorial base.
All are or were involved in the preparation of systematic reviews. This protocol is not supported by the pharmaceutical industry or by any grant.
J. Bohlius gave two presentations on erythropoiesis‐stimulating agents at Hoffmann‐La Roche & Co, the manufacturer of rituximab.
M. Reiser, M. Herold, M. Dreyling, and M. Hallek have conducted research sponsored by Hoffmann‐La Roche & Co, the manufacturer of rituximab. M. Herold is a member of the Hoffmann‐La Roche & Co Speaker's bureau, and M. Dreyling has received a speaker's honorarium from Hoffmann‐La Roche & Co. M. Herold is a member of the Hoffmann‐La Roche & Co advisory board.
.

Acknowledgements

We thank all authors and investigators who provided us with additional information. We thank the editors of and the consumers of the Cochrane Hematological Malignancies Group for strong support.
The CHMG is funded by the German Ministry of Education and Research (BMBF), Grant application No.: 01GH501 and gets additional funding by "Köln Fortune" the funding programme from the medical faculty University of Cologne.

Version history

Published

Title

Stage

Authors

Version

2007 Oct 17

Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma

Review

Holger Schulz, Julia Bohlius, Nicole Skoetz, Sven Trelle, Thilo Kober, Marcel Reiser, Martin Dreyling, Michael Herold, Guido Schwarzer, Michael Hallek, Andreas Engert

https://doi.org/10.1002/14651858.CD003805.pub2

2002 Oct 21

Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma

Protocol

Thilo Kober, Tom O Klein, Julia Bohlius, Andreas Engert

https://doi.org/10.1002/14651858.CD003805

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.